Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Publication date: Mar 13, 2019

This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Concepts Keywords
Adrenal MRI
Alanine Aminotransferase Antibodies
Alopecia Adjuvant therapy
ALT Magnetic resonance imaging
Aminotransferase Brain metastasis
Antibody Pembrolizumab
Anticoagulant Melanoma
Anticoagulants Ipilimumab
Antigen Radiobiology
APTT Neurosurgery
Aspartate Radiation therapy
AST Cancer treatments
Autoimmune Disease Medicine
Basal Clinical medicine
Bilirubin Brain Immunotherapy
Biopsies Adjuvant therapy
Biopsy Conformal radiotherapy
Birth Control Birth control
Blood Catheter
Brain Major surgery
Breastfeeding Hormone replacement
Cancer Steroids current pneumonitis
Carcinoma Reactive hepatitis hepatitis
Cerebrospinal Fluid Tumor
Cervix Free neurologic signs
Concurrent Contraceptive guidance protocol
Conformal Related venous thrombosis
Contraceptive HCV
Cooperative Group Eligibility Hepatitis
Corticosteroid Significant traumatic injury
Corticosteroids Non infectious pneumonitis
CrCl Active infection
Creatinine Basal squamous carcinoma
Creatinine Clearance Total viable tumor
Cytokine Onset angina
Deoxyribonucleic Acid Ability tumor
Dexamethasone HIV
Diabetes Mellitus
Diffusion Coefficient
Fine Needle Aspiration
Forceps
Formalin
Glomerular Filtration Rate
HBsAg
HCV
Hemoglobin
Hepatitis
Histologically
HIV
Hormone
Hypothyroidism
IEC
Immune System Attack
Immunodeficiency
Immunosuppressive Medications
Immunotherapy
Infection
Informed Consent
INR
Intravenously
Ipilimumab
IRB
Leptomeningeal
Lesion
Liver
Local Authority
Lumbar Puncture
Magnetic Resonance Imaging
Malignancy
Malignant Melanoma
Melanoma
Metastases
Metastasis
Metastatic
Monoclonal Antibodies
MRI
Normalized
Oncology
Paraffin
Pathology
Platelets
Pleural Effusion
Prednisone
Pregnancy Test
Progressive
Prostate Specific Antigen
Protein
Prothrombin
Protocol
Psoriasis
Psychiatric Condition
Radiotherapy
Representative
Ribonucleic Acid
RNA
Sequelae
Sperm
Squamous Carcinoma
SRT
Stereotactic
Steroids
Subcutaneous
T Cell
Therapeutic Range
Tolerability
Topical
Toxicity
Tumor
Virus
Vitiligo
Washout

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
disease MESH pneumonitis
gene UNIPROT EHD1
disease DOID myocardial infarction
disease MESH myocardial infarction
gene UNIPROT REST
disease DOID unstable angina
disease MESH unstable angina
disease DOID congestive heart failure
disease MESH congestive heart failure
disease MESH cardiac disease
disease DOID pulmonary embolism
disease MESH pulmonary embolism
disease MESH deep vein thrombosis
disease DOID cerebrovascular accident
disease MESH cerebrovascular accident
disease MESH ulcer
disease DOID skin cancer
disease MESH skin cancer
drug DRUGBANK Prednisone
drug DRUGBANK Dexamethasone
disease MESH infection
pathway BSID Hepatitis C
disease DOID hepatitis C
disease MESH hepatitis C
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
pathway BSID Hepatitis B
disease DOID hepatitis B
disease MESH hepatitis B
disease DOID carcinoma
disease MESH carcinoma
disease DOID alopecia
disease MESH alopecia
disease DOID psoriasis
disease MESH psoriasis
disease DOID vitiligo
disease MESH vitiligo
disease DOID hypothyroidism
disease MESH hypothyroidism
pathway BSID Type I diabetes mellitus
disease DOID type I diabetes mellitus
disease DOID autoimmune disease
disease MESH autoimmune disease
gene UNIPROT SNCA
gene UNIPROT SPATA2
gene UNIPROT PDCD1
gene UNIPROT RPL17
gene UNIPROT ELL
disease MESH men
drug DRUGBANK Prothrombin
gene UNIPROT CD274
drug DRUGBANK Formaldehyde
gene UNIPROT CYREN
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
disease MESH metastases
disease DOID cancer
disease MESH cancer
pathway BSID Immune System
disease DOID Melanoma
pathway BSID Melanoma
disease MESH Melanoma
drug DRUGBANK Pembrolizumab
drug DRUGBANK Ipilimumab
drug DRUGBANK L-Alanine
gene UNIPROT SLC17A5
gene UNIPROT RAPGEF5
drug DRUGBANK Creatinine
disease MESH neurologic signs and symptoms
disease MESH Growth
disease MESH sequelae
disease MESH pleural effusion

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *